Trulieve Reports $79.7 Million Q4 Revenue and Reaffirms 2020 Outlook

Trulieve Reports Fourth Quarter and Full Fiscal Year 2019 Financial Results

A strong year end with continued operational success supported by industry leading profitability

TALLAHASSEE, FL, April 8, 2020 /CNW/ – Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States, today announced its financial results for the three and 12 months ended December 31, 2019. Unless otherwise stated, all currency is expressed in U.S. dollars.

Fourth Quarter 2019 Financial & Operational Highlights

• Achieved record revenue of  $79.7 million , an increase of 13% on a sequential quarter-to-quarter basis
• Adjusted EBITDA^1,2 increased from  $36.9 million  in Q3 2019 to  $45.0 million  in Q4 2019
• Significant, sustained market share in  Florida , demonstrating Trulieve’s ability to maintain its brand and customer loyalty
• Continued initiatives for the optimization of efficiencies and economies of scale
• Enhanced strategic capabilities with the appointment of  Susan Thronson  and  Thomas Millner  to serve as advisors to the Trulieve Board of Directors
• Appointed  Valda Coryat  as Chief Marketing Officer, adding extensive consumer packaged goods and agricultural experience
• Opened seven additional dispensaries in  Florida  in the fourth quarter, to reach 44 stores nationally at  December 31, 2019
• Increased total current cultivation capacity to approximately 1.7 million square feet, with plans to continue indoor cultivation build-out at  Jefferson County, FL  location to match expected demand

Recent Highlights & Developments

• Implemented quick changes in response to COVID-19 pandemic, including adding health and safety procedures for employees and facilities, increasing production rates to ensure adequate supply in stores, and investments in vehicles in anticipation of increased delivery demand

Our fourth quarter results reflect our strong brand and customer loyalty, which were key factors in our success for the year. We continued to grow our footprint in  Florida  and made significant strides building out the infrastructure needed to maximize efficiencies and achieve economies of scale.

Kim Rivers , Trulieve CEO.

Despite recent developments surrounding COVID-19 and the uncertainty in the global economy, we see strong medical cannabis demand in our target markets and expect to continue maintaining our over 50% market share in Florida.  Our solid foundation and cash position enable us to monitor opportunities that meet our disciplined criteria and we remain optimistic about expansion in 2020.

2019 Quarterly and Full Year Financial Highlights

The Company determined that share-based compensation expense for previously disclosed warrants was understated by approximately  $15.0 million  in the reported financial statements for the year ended  December 31, 2018 . Adjustments to the audited consolidated financial statements for the year ended 2018 to account for the understatement are summarized in Note 2 of the audited consolidated financial statements for the year ended 2019.

The Management Discussion and Analysis for the period and the accompanying financial statements and notes are available under the Company’s profile on SEDAR at www.sedar.com  and on its website at https://www.trulieve.com/investors.

This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.

Financial Guidance

Reflecting continued leverage of scale and financial discipline, the Company is reaffirming guidance for full year 2020. Guidance for 2020 can be found in our first quarter press release available at: https://www.newswire.ca/news-releases/trulieve-reports-another-quarter-of-record-revenue-898676764.html

Conference Call

The Company will host a conference call and live audio webcast on 2020,  April 8, 2020  at  8:30 A.M. Eastern time , to discuss its fourth quarter 2019 financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 9576534. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until  April 14, 2020  at midnight, ET. To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 9576534.

A live audio webcast of the conference call will be available at: https://produceredition.webcasts.com/starthere.jsp?ei=1294031&tp_key=ea54bd8915

Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 90 days by clicking the link above.

Non-IFRS Measures

Adjusted EBITDA is not a recognized performance measure under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. Adjusted EBITDA is included as a supplemental disclosure because Management believes that such measurement provides a better assessment of the Company’s operations on a continuing basis by eliminating certain material non-cash items and certain other adjustments Management believes are not reflective of the Company’s ongoing ?operations and performance?. Adjusted EBITDA has limitations as an analytical tool as it excludes from net income as reported interest, tax, depreciation, non-cash ?expenses, RTO expense, other income, grow cost expensed for biological assets and unsold inventory, ?and the non-cash fair value effects of accounting for biological assets and inventories. Because of these limitations, Adjusted EBITDA should not be considered as the sole measure of the Company’s performance and should not be considered in isolation from, or as a substitute for, analysis of the Company’s results as reported under IFRS. The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is operating income (loss). See “Reconciliation of non-IFRS measures” in the Company’s Management’s Discussion and Analysis for the year ended  December 31, 2019  for additional information.

About Trulieve Cannabis Corp.

Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the  State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the  State of Florida , as well as directly to patients via home delivery. Trulieve also operates in  California ,  Massachusetts  and  Connecticut . Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of  the United States  and may not be offered or sold within  the United States  (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

To learn more about Trulieve, visit www.Trulieve.com.

Original Press Release

Published by NCV Newswire

The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.